Skip to content
Menu
CBD MEDICAL NETWORK
  • Das CBD Medical Network mit Infothek
  • Das Netzwerk („in incrementum“)
  • Kontakt
CBD MEDICAL NETWORK

Inhibition of colon carcinogenesis

Posted on 20. Februar 2020

Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol.

PubMed

PURPOSE:
Colon cancer is a major public health problem. Cannabis-based medicines are useful adjunctive treatments in cancer patients.

Here, we have investigated the effect of a standardized Cannabis sativa extract with high content of cannabidiol (CBD), here named CBD BDS, i.e. CBD botanical drug substance, on colorectal cancer cell proliferation and in experimental models of colon cancer in vivo.

RESULTS:
CBD BDS and CBD reduced cell proliferation in tumoral, but not in healthy, cells. The effect of CBD BDS was counteracted by selective CB1 and CB2 receptor antagonists. Pure CBD reduced cell proliferation in a CB1-sensitive antagonist manner only. In binding assays, CBD BDS showed greater affinity than pure CBD for both CB1 and CB2 receptors, with pure CBD having very little affinity. In vivo, CBD BDS reduced AOM-induced preneoplastic lesions and polyps as well as tumour growth in the xenograft model of colon cancer.

CONCLUSIONS:
CBD BDS attenuates colon carcinogenesis and inhibits colorectal cancer cell proliferation via CB1 and CB2 receptor activation. The results may have some clinical relevance for the use of Cannabis-based medicines in cancer patients.

Zum Artikel.

Unsere Info-Mails

Aktuelle Beiträge in der Infothek

  • TRPV1 schützt Neuronen bei Multipler Sklerose
  • CBD im Einsatz gegen CoVid.
  • Gedanken zu den ersten Cannabinoiden bzw. den Säure-Vorstufen
  • Das antimikrobielle Potenzial von Cannabidiol
  • Cannabigerol (CBG) aus pharmakologischer Sicht

Nach Stichworten suchen

Impressum & Datenschutz

Impressum & Datenschutz

Rechtliches

Impressum & Datenschutz

©2023 CBD MEDICAL NETWORK | Powered by SuperbThemes!